.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,897,646

« Back to Dashboard

Claims for Patent: 7,897,646

Title:Use for budesonide and formoterol
Abstract:The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
Inventor(s): Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/010,283
Patent Claims: 1. A method for reducing the frequency and/or intensity of chronic obstructive pulmonary disease (COPD) exacerbations experienced by a patient suffering from COPD, which method comprises administering to the patient via inhalation (i) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; and (ii) a second active ingredient which is budesonide, wherein the method is effective to reduce the frequency and/or intensity of exacerbations in the patient, the first and second active ingredients are administered simultaneously, and the molar ratio of (a) formoterol in the first active ingredient to (b) the second active ingredient is from 1:555 to 2:1.

2. A method according to claim 1, wherein the first and/or second active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents and/or carriers.

3. A method according to claim 1, wherein the first active ingredient is formoterol fumarate dihydrate.

4. A method according to claim 1, wherein the molar ratio is from 1:133 to 1:6.

5. A method according to claim 4 wherein the molar ratio is from 1:70 to 1:4.

6. A method according to claim 1, wherein the first and second active ingredients are provided in powder form.

7. A method according to claim 6 wherein the first and second active ingredients are formulated as powder particles having a mass median diameter of less than 10 .mu.m.

8. A method according to claim 1 wherein the first and second active ingredients are provided in the form of an admixture.

9. A method according to claim 1 wherein the first active ingredient is administered to the patient in one or more unit doses per day, the amount of formoterol delivered to the patient by each unit dose of the first active ingredient being from about 2 to 120 nmol.

10. A method according to claim 9 wherein the amount of formoterol delivered to the patient by each unit dose of the first active ingredient is from about 7 to 70 nmol.

11. A method according to claim 1 wherein the second active ingredient is administered to the patient in one or more unit doses per day, the amount of budesonide delivered to the patient by each unit dose being from about 0.1 to 5 .mu.mol.

12. A method according to claim 11 wherein the amount of budesonide delivered to the patient by each unit dose is from about 0.15 to 4 .mu.mol.

13. A method according to claim 3 wherein the formoterol fumarate dihydrate is administered to the patient in one or more unit doses per day, the amount of formoterol fumarate dihydrate delivered to the patient by each unit dose being from about 1 to 50 .mu.g.

14. The method of claim 1, further comprising monitoring the number of exacerbations experienced by the patient over a period of 12 months of treatment.

15. The method of claim 1, wherein the first active ingredient is administered in the form of one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 4.5 .mu.g of formoterol fumarate dihydrate to the patient; and the second active ingredient is administered in the form of one or more unit doses of budesonide, each unit dose of budesonide delivering 160 .mu.g of budesonide to the patient.

16. The method of claim 15, wherein the unit doses of both the formoterol fumarate dihydrate and the budesonide are administered one to four times per day.

17. The method of claim 1, wherein the first and second active ingredients are administered together from a pressurized metered dose inhaler (pMDI).

18. The method of claim 1, wherein at least one of the first and second active ingredients is formulated in a propellant comprising one or both of P227 (heptafluoropropane) and P134(a) (tetrafluoroethane).

19. The method of claim 3, wherein the first and second active ingredients are provided in admixture.

20. The method of claim 19, wherein the first and second active ingredients are in powder form.

21. The method of claim 20, wherein the first and second active ingredients are administered in admixture in the form of unit doses, each unit dose delivering to the patient 4.5 .mu.g formoterol fumarate dihydrate and 160 .mu.g budesonide.

22. The method of claim 21, wherein the patient is administered one to four of the unit doses per day.

23. The method of claim 20, wherein the first and second active ingredients are administered in admixture in the form of unit doses, each unit dose delivering to the patient 9 .mu.g formoterol fumarate dihydrate and 320 .mu.g budesonide.

24. The method of claim 23, wherein the patient is administered one or two of the unit doses per day.

25. The method of claim 1, wherein the first active ingredient is in the form of one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 4.5 .mu.g of formoterol fumarate dihydrate to the patient; and the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered in the form of one or more unit doses of budesonide, each unit dose of budesonide delivering 80 .mu.g of budesonide to the patient.

26. The method of claim 25, wherein the unit doses of both the first active ingredient and the second active ingredient are administered one to four times per day.

27. The method of claim 1, wherein the first active ingredient is administered in the form of one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 9 .mu.g of formoterol fumarate dihydrate to the patient; and the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered in the form of one or more unit doses of budesonide, each unit dose of budesonide delivering 160 .mu.g of budesonide to the patient.

28. The method of claim 27, wherein the unit doses of both the first active ingredient and the second active ingredient are administered once or twice per day.

29. A method for the treatment of a patient suffering from COPD, which method comprises administering to the patient via inhalation (i) a daily dose of a first active ingredient that is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, the daily dose of the first active ingredient delivering 2 to 120 nmol of formoterol to the patient; and (ii) a daily dose of a second active ingredient that is budesonide, the daily dose of the second active ingredient delivering 45 to 2200 .mu.g of budesonide to the patient, wherein the first active ingredient, which may be separate from or in admixture with the second active ingredient, is administered simultaneously with the second active ingredient, and wherein the daily dose of each active ingredient is administered in one to four divided doses per day.

30. The method of claim 29, wherein each daily dose of the first active ingredient is administered as one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 9 .mu.g of formoterol fumarate dihydrate to the patient; and each daily dose of the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered as one or more unit doses of budesonide, each unit dose of budesonide delivering 320 .mu.g of budesonide to the patient.

31. The method of claim 30, wherein the unit doses of both the formoterol fumarate dihydrate and the budesonide are administered once or twice per day.

32. The method of claim 29, wherein each daily dose of the first active ingredient is administered as one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 4.5 .mu.g formoterol fumarate dihydrate to the patient; and each daily dose of the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered as one or more unit doses of budesonide, each unit dose delivering 80 .mu.g of budesonide to the patient.

33. The method of claim 29, wherein each daily dose of the first active ingredient is administered as one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 9 .mu.g formoterol fumarate dihydrate to the patient; and each daily dose of the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered as one or more unit doses of budesonide, each unit dose delivering 160 .mu.g of budesonide to the patient.

34. The method of claim 33, wherein the unit doses of both the first active ingredient and the second active ingredient are administered once or twice per day.

35. The method of claim 29, wherein each daily dose of the first active ingredient is administered as one or more unit doses of formoterol fumarate dihydrate, each unit dose delivering 4.5 .mu.g formoterol fumarate dihydrate to the patient; and each daily dose of the second active ingredient, which may be separate from or in admixture with the first active ingredient, is administered as one or more unit doses of budesonide, each unit dose delivering 160 .mu.g of budesonide to the patient.

36. The method of claim 29, wherein the first and second active ingredients are administered together from a single pMDI.

37. The method of claim 29, wherein at least one of the first and second active ingredients is formulated in a propellant comprising one or both of P227 and P134(a).

38. The method of claim 29, wherein the method produces a reduction in frequency or intensity of COPD exacerbations in the patient.

39. The method of claim 29, wherein the method produces an improvement in FEV.sub.1 in the patient.

40. A method for treating a patient suffering from COPD, which method comprises administering to the patient, via inhalation from a pMDI, a composition comprising (i) a first active ingredient that is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt; (ii) a second active ingredient that is budesonide; and (iii) propellant P227, wherein the molar ratio of (a) formoterol in the first active ingredient to (b) the second active ingredient is from 1:70 to 1:4.

41. The method of claim 40, wherein the patient inhales 4.5 or 9.0 .mu.g formoterol fumarate dihydrate once or twice per day and 80 or 160 .mu.g budesonide once or twice per day.

42. The method of claim 40, wherein the method produces a reduction in frequency or intensity of COPD exacerbations in the patient.

43. The method of claim 40, wherein the method produces an improvement in FEV.sub.1 in the patient.

44. A method for the treatment of a patient suffering from COPD, which method comprises administering formoterol fumarate dihydrate and budesonide to the patient via inhalation, wherein the formoterol fumarate dihydrate and budesonide are administered simultaneously and optionally in admixture; the amount of formoterol fumarate dihydrate inhaled by the patient is 18 .mu.g per day; and the amount of budesonide inhaled by the patient is 640 .mu.g per day.

45. A method for the treatment of a patient suffering from COPD, which method comprises administering to the patient via inhalation (i) a daily dose of a first active ingredient that is formoterol, a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, the daily dose of the first active ingredient delivering an amount of formoterol to the patient per day that is equivalent to the amount delivered when 18 .mu.g of formoterol fumarate dihydrate per day is delivered to the patient; and (ii) a daily dose of a second active ingredient that is budesonide, the daily dose of the second active ingredient delivering 640 .mu.g of budesonide to the patient per day, wherein the first active ingredient is optionally in admixture with the second active ingredient, and the two active ingredients are administered simultaneously.

46. A method for the treatment of a patient suffering from COPD, which method comprises administering formoterol fumarate dihydrate and budesonide to the patient via inhalation, wherein the formoterol fumarate dihydrate and budesonide are administered simultaneously, and optionally in admixture, in one to four unit doses per day; the amount of formoterol fumarate dihydrate delivered to the patient by each unit dose of formoterol fumarate dihydrate is 4.5 .mu.g; and the amount of budesonide delivered to the patient by each unit dose of budesonide is 160 .mu.g.

47. The method according to claim 40, wherein the patient inhales 4.5 .mu.g of formoterol fumarate dihydrate and 160 .mu.g of budesonide as a unit dose one to four times per day.

48. The method according to claim 40, wherein the composition further comprises one or more other excipients.

49. The method according to claim 47, wherein the composition further comprises one or more other excipients.

50. The method according to claim 48, wherein the one or more other excipients is selected from ethanol, a lubricant, an antioxidant, and a stabilizing agent.

51. The method according to claim 49, wherein the one or more other excipients is selected from ethanol, a lubricant, an antioxidant, and a stabilizing agent.

52. The method according to claim 47, wherein the formoterol fumarate dihydrate and budesonide are in the form of micronized particles.

53. The method according to claim 44, wherein the formoterol fumarate dihydrate and the budesonide are in admixture and are formulated in a composition comprising a propellant.

54. The method according to claim 45, wherein the formoterol fumarate dihydrate and the budesonide are in admixture and are formulated in a composition comprising a propellant.

55. The method according to claim 46, wherein the formoterol fumarate dihydrate and the budesonide are in admixture and are formulated in a composition comprising a propellant.

56. The method according to claim 53, wherein the propellant comprises one or both of P227 and P134(a).

57. The method according to claim 54 wherein the propellant comprises one or both of P227 and P134(a).

58. The method according to claim 55, wherein the propellant comprises one or both of P227 and P134(a).

59. The method according to claim 53, wherein the composition further comprises one or more other excipients.

60. The method according to claim 54, wherein the composition further comprises one or more other excipients.

61. The method according to claim 55, wherein the composition further comprises one or more other excipients.

62. The method according to claim 59, wherein the one or more other excipients is selected from ethanol, a lubricant, an antioxidant, and a stabilizing agent.

63. The method according to claim 60, wherein the one or more other excipients is selected from ethanol, a lubricant, an antioxidant, and a stabilizing agent.

64. The method according to claim 61, wherein the one or more other excipients is selected from ethanol, a lubricant, an antioxidant, and a stabilizing agent.

65. The method according to claim 53, wherein the formoterol fumarate dihydrate and budesonide are in the form of micronized particles.

66. The method according to claim 54, wherein the formoterol fumarate dihydrate and budesonide are in the form of micronized particles.

67. The method according to claim 55, wherein the formoterol fumarate dihydrate and budesonide are in the form of micronized particles.

68. The method according to claim 53, wherein the formoterol fumarate dihydrate and the budesonide are administered together from a single pMDI.

69. The method according to claim 54, wherein the formoterol fumarate dihydrate and the budesonide are administered together from a single pMDI.

70. The method according to claim 55, wherein the formoterol fumarate dihydrate and the budesonide are administered together from a single pMDI.

71. The method according to claim 44, wherein the formoterol fumarate dihydrate and the budesonide are in admixture.

72. The method according to claim 45, wherein the formoterol fumarate dihydrate and the budesonide are in admixture.

73. The method according to claim 46, wherein the formoterol fumarate dihydrate and the budesonide are in admixture.

74. The method according to claim 71, wherein the formoterol fumarate dihydrate and the budesonide are in the form of a dry powder.

75. The method according to claim 72, wherein the formoterol fumarate dihydrate and the budesonide are in the form of a dry powder.

76. The method according to claim 73, wherein the formoterol fumarate dihydrate and the budesonide are in the form of a dry powder.

77. The method according to claim 71, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an agglomerated, micronized dry powder.

78. The method according to claim 72, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an agglomerated, micronized dry powder.

79. The method according to claim 73, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an agglomerated, micronized dry powder.

80. The method according to claim 71, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an ordered mixture with a pharmaceutically acceptable additive, diluent or carrier.

81. The method according to claim 72, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an ordered mixture with a pharmaceutically acceptable additive, diluent or carrier.

82. The method according to claim 73, wherein the formoterol fumarate dihydrate and the budesonide are in the form of an ordered mixture with a pharmaceutically acceptable additive, diluent or carrier.

83. The method according to claim 71, wherein the formoterol fumarate dihydrate and the budesonide are administered to the patient from a dry powder inhaler.

84. The method according to claim 72, wherein the formoterol fumarate dihydrate and the budesonide are administered to the patient from a dry powder inhaler.

85. The method according to claim 73, wherein the formoterol fumarate dihydrate and the budesonide are administered to the patient from a dry powder inhaler.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc